A decent end to FY24: investors jittery with biopharma headwinds
31/01/25 -"During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was attributable to continued weakness in the Biopharma ..."
Pages
47
Language
English
Published on
31/01/25
You may also be interested by these reports :
21/10/25
Eurofins Scientific’s Q3 results were broadly in line with our expectations and Visible Alpha consensus. The organic growth was slightly below ...
07/10/25
FICO’s launch of the Mortgage Direct Licence Programme – which allows resellers to obtain scores directly from them, thereby bypassing credit ...
23/09/25
After a decent close to 2024 (i.e. March-end FY25), management guidance for 2025 seemed overambitious, given the macro environment, especially ...
04/09/25
The change in the target price reflects the update of our estimates and the effect on DCF and peer-based valuations. Despite a challenging macro ...